Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Claudio Bonometti

Clinical Cardiac Electrophysiology Las Vegas, NV Medical Doctor

NPI 1053326728 CMS profile 320168

3150 N Tenaya Way Ste 320, Las Vegas, NV 89128

Open in the dashboard

General payments

$88,750

919 records reported · program years 2019–2025

Research payments

$11,164

Paid to them · 49 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,445 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Claudio Bonometti of Las Vegas, NV is reported in the CMS Open Payments database as having received $88,750 across 919 general payments and $11,164 in research payments paid to them. Separately, studies naming them as principal investigator received $2,445 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,397 132
2024 General $9,020 148
2023 General $7,019 135
2022 General $8,497 126
2021 General $7,791 121
2020 General $12,473 83
2019 General $35,552 174
2019 Research $11,164 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claudio Bonometti
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Claudio Bonometti were reported at $8,397. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Claudio Bonometti Clinical Cardiac Electrophysiology median Middle half National median
2019 $35,552 $2,361 $585–$8,260 $163
2020 $12,473 $993 $247–$4,351 $114
2021 $7,791 $1,185 $326–$4,739 $132
2022 $8,497 $2,073 $554–$6,789 $149
2023 $7,019 $2,568 $759–$8,159 $160
2024 $9,020 $2,557 $703–$7,403 $164
2025 $8,397 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biosense Webster, Inc. $30,824 364 payments
  2. Janssen Pharmaceuticals, Inc $25,084 56 payments
  3. Abbott Laboratories $8,250 67 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6,577 33 payments
  5. Biotronik Inc. $5,601 32 payments
  6. Medtronic, Inc. $1,619 36 payments
  7. Medtronic Vascular, Inc. $1,458 20 payments
  8. CardioFocus, Inc. $1,342 18 payments
  9. Merck Sharp & Dohme Corporation $945 33 payments
  10. Amgen Inc. $870 84 payments
  11. Other $6,181 176 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $52,953 888 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,100 15 payments
  3. Consulting Fee $3,100 4 payments
  4. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,400 1 payment
  5. Travel and Lodging $1,166 9 payments
  6. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $25,084 56 payments
  2. Carto 3 $19,757 238 payments
  3. Carto 3 System $11,302 117 payments
  4. LifeVest $6,577 33 payments
  5. Perclose ProGlide suture mediated closure system $2,899 6 payments
  6. VISITAG SURPOINT External Processing Unit $1,621 18 payments
  7. CARDIOMEMS $1,282 16 payments
  8. VERQUVO $1,248 37 payments
  9. Soundstar $1,143 14 payments
  10. Heartlight System $1,135 15 payments
  11. Other $19,430 418 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Biotronik Inc. $11,164 49 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,783

Median for Cardiology: 2,533

Drug cost

$1,237,526

Median for Cardiology: $485,213

Branded share of claims

37.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 333 $393,135
Entresto Sacubitril/Valsartan Brand 173 $277,551
Verquvo Vericiguat Brand 116 $166,962
Multaq Dronedarone Hcl Brand 65 $114,140
Repatha Sureclick Evolocumab Brand 100 $94,220
Xarelto Rivaroxaban Brand 65 $89,284
Brilinta Ticagrelor Brand 35 $26,591
Farxiga Dapagliflozin Propanediol Brand 17 $20,145
Ozempic Semaglutide Brand 11 $16,342
Livalo Pitavastatin Calcium Brand 13 $10,764

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$695,931

Medicare's payments for the services billed

Medicare patients

2,580

Average age 76

Services billed

11,462

1,161 women, 1,419 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Atrial fibrillation 52%
Arthritis 47%
Diabetes 46%
Heart failure 44%
Chronic kidney disease 41%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
$303 116 —
Repatha
$159 100 —
LEQVIO
$148 — —
CAMZYOS
$103 — —
XARELTO
$90 65 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

968 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record